These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 22553332)

  • 21. Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer.
    Alsahafi N; Debbeche O; Sodroski J; Finzi A
    PLoS One; 2015; 10(4):e0122111. PubMed ID: 25849367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation.
    Guzzo C; Zhang P; Liu Q; Kwon AL; Uddin F; Wells AI; Schmeisser H; Cimbro R; Huang J; Doria-Rose N; Schmidt SD; Dolan MA; Connors M; Mascola JR; Lusso P
    mBio; 2018 Dec; 9(6):. PubMed ID: 30538178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies.
    Gardner MR; Fellinger CH; Prasad NR; Zhou AS; Kondur HR; Joshi VR; Quinlan BD; Farzan M
    J Virol; 2016 Sep; 90(17):7822-32. PubMed ID: 27334589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.
    Broder CC; Earl PL; Long D; Abedon ST; Moss B; Doms RW
    Proc Natl Acad Sci U S A; 1994 Nov; 91(24):11699-703. PubMed ID: 7972127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.
    Go EP; Ding H; Zhang S; Ringe RP; Nicely N; Hua D; Steinbock RT; Golabek M; Alin J; Alam SM; Cupo A; Haynes BF; Kappes JC; Moore JP; Sodroski JG; Desaire H
    J Virol; 2017 May; 91(9):. PubMed ID: 28202756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
    Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.
    Edwards TG; Wyss S; Reeves JD; Zolla-Pazner S; Hoxie JA; Doms RW; Baribaud F
    J Virol; 2002 Mar; 76(6):2683-91. PubMed ID: 11861835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Connections: Cell-to-Cell HIV-1 Transmission, Resistance to Broadly Neutralizing Antibodies, and an Envelope Sorting Motif.
    Smith SA; Derdeyn CA
    J Virol; 2017 May; 91(9):. PubMed ID: 28250119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.
    Diomede L; Nyoka S; Pastori C; Scotti L; Zambon A; Sherman G; Gray CM; Sarzotti-Kelsoe M; Lopalco L
    J Virol; 2012 Apr; 86(8):4129-38. PubMed ID: 22301151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity.
    Bradley T; Trama A; Tumba N; Gray E; Lu X; Madani N; Jahanbakhsh F; Eaton A; Xia SM; Parks R; Lloyd KE; Sutherland LL; Scearce RM; Bowman CM; Barnett S; Abdool-Karim SS; Boyd SD; Melillo B; Smith AB; Sodroski J; Kepler TB; Alam SM; Gao F; Bonsignori M; Liao HX; Moody MA; Montefiori D; Santra S; Morris L; Haynes BF
    EBioMedicine; 2016 Oct; 12():196-207. PubMed ID: 27612593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.
    Powell RLR; Totrov M; Itri V; Liu X; Fox A; Zolla-Pazner S
    J Virol; 2017 Sep; 91(17):. PubMed ID: 28615206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.
    Broliden PA; von Gegerfelt A; Clapham P; Rosen J; Fenyö EM; Wahren B; Broliden K
    Proc Natl Acad Sci U S A; 1992 Jan; 89(2):461-5. PubMed ID: 1370580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.
    Chen Y; Wilson R; O'Dell S; Guenaga J; Feng Y; Tran K; Chiang CI; Arendt HE; DeStefano J; Mascola JR; Wyatt RT; Li Y
    J Immunol; 2016 Nov; 197(10):3982-3998. PubMed ID: 27815444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes.
    Das S; Boliar S; Mitra N; Samal S; Bansal M; Koff WC; Chakrabarti BK
    Retrovirology; 2016 Nov; 13(1):81. PubMed ID: 27871328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.
    Li Y; O'Dell S; Wilson R; Wu X; Schmidt SD; Hogerkorp CM; Louder MK; Longo NS; Poulsen C; Guenaga J; Chakrabarti BK; Doria-Rose N; Roederer M; Connors M; Mascola JR; Wyatt RT
    J Virol; 2012 Oct; 86(20):11231-41. PubMed ID: 22875963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.
    Earl PL; Broder CC; Long D; Lee SA; Peterson J; Chakrabarti S; Doms RW; Moss B
    J Virol; 1994 May; 68(5):3015-26. PubMed ID: 7512157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.
    Trott M; Weiβ S; Antoni S; Koch J; von Briesen H; Hust M; Dietrich U
    PLoS One; 2014; 9(5):e97478. PubMed ID: 24828352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.
    Blattner C; Lee JH; Sliepen K; Derking R; Falkowska E; de la Peña AT; Cupo A; Julien JP; van Gils M; Lee PS; Peng W; Paulson JC; Poignard P; Burton DR; Moore JP; Sanders RW; Wilson IA; Ward AB
    Immunity; 2014 May; 40(5):669-80. PubMed ID: 24768348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
    Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.